No Data
Why Investors Shouldn't Be Surprised By Shenyang Xingqi Pharmaceutical Co.,Ltd.'s (SZSE:300573) Low P/E
Sinqi Pharmaceutical: Report for the first quarter of 2025
Shenyang Xingqi Pharmaceutical (300573.SZ): In the first quarter, the net income was 0.146 billion yuan, a year-on-year increase of 319.86%.
On April 28, Gelonghui reported that Shenyang Xingqi Pharmaceutical (300573.SZ) released its first-quarter report for 2025, showing revenue of 0.536 billion yuan, a year-on-year increase of 53.24%; net income attributable to shareholders of the listed company was 0.146 billion yuan, a year-on-year increase of 319.86%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.136 billion yuan, a year-on-year increase of 285.96%; basic EPS was 0.83 yuan.
Shenyang Xingqi Pharmaceutical experienced double increases in revenue and net profit last year, with short-term loans significantly rising compared to the beginning of the year | Interpretations
In 2024, both revenue and Net income increased, but there was a significant drop in Net income in the fourth quarter. Throughout the year, multiple loans were taken from Banks for the company's daily Operation turnover, with short-term borrowings exceeding 0.2 billion by the end of the year.
Sinqi Pharmaceutical: 2024 Annual Report Summary
Sinqi Pharmaceutical: 2024 Annual Report
Market Participants Recognise Shenyang Xingqi Pharmaceutical Co.,Ltd.'s (SZSE:300573) Revenues Pushing Shares 26% Higher
